BIOTRON LIMITED — Investor Presentation 2011

Jan 11, 2011

==> picture [227 x 36] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

12 January 2011

The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000

(18 pages by email)

Dear Madam,

US BIOTECH SHOWCASE PRESENTATION

Biotron's Managing Director, Dr Michelle Miller, has presented an update of the Company's activities to an international audience at the Biotech Showcase 2011 in San Francisco, USA.

In addition, Dr Miller has given briefings to US institutional investors and pharmaceutical company representatives as part of activities surrounding the annual JP Morgan Healthcare Conference currently underway in San Francico.

The Biotech Showcase features corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco.

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.

Yours faithfully

==> picture [111 x 71] intentionally omitted <==

Peter J. Nightingale Company Secretary pjn5802

==> picture [721 x 136] intentionally omitted <==

BIOTRON LIMITED ASX:BIT

January 2011

Michelle Miller CEO & Managing Director

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

‐ This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they ‐ relate to Biotron Limited, are intended to identify forward looking statements. By ‐ their nature, forward looking statements involve risk and uncertainty because they reflect Biotron ’ s current expectations and assumptions as to future events and circumstances that not accurate. There is no that the may prove guarantee expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

• Established in 1999 as a spin-out from the Australian National University, Canberra; Currently based in Sydney, Australia

• IPO on ASX in Jan 2001 (ASX:BIT)

• Focus on developing novel small molecule antiviral drugs

• Hep C, HIV, Dengue and others

• Key highlights

• Successful implementation of clinical trials for the Hep C and HIV programs

• Successful capital raisings in challenging market conditions

  • A$2.7 m (net of costs) in 2010

  • A$20 . 75 m since foundation

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

Ca ital Structure & Financials
p
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

Shares on issue 121.8 m Listed options 108 m No. Shareholders ~1500 T 20 42 .5 1 % une op (30 J 2010) Current S/P A$0 . 12 52 wk high/ low A$0.15/ 0.051 Market ca p A $ 14.6 m ( 10 Jan 11 ) Cash at 30 Sept 10 A$1.44 m

Biotron Limited

==> picture [721 x 68] intentionally omitted <==

• Identification of new class of viral proteins called viroporins

• Small hydrophobic proteins with ion channel activity

• Key roles in production and release of infectious virus

• Present in influenza (M2), HIV (Vpu), Hep C (p7), Dengue (M) , SARS (E) and others

• Ongoing need for new drugs to overcome viral resistance; patients are treated with cocktails of antiviral drugs

• Designed library of new drugs to target these viral targets

• 350 compounds designed , synthesised and screened

• Developed proprietary bacterial screening assays for HIV-1 Vpu, HCV p7, Coronavirus E, Influenza M2, and Dengue M protein.

• Generating first-in-class drugs to treat these diseases

• Initial focus on HIV and Hep C

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

• Two clinical phase programs:

– Hepatitis C virus (BIT225) and HIV

– Both have very large, expanding world markets

• Current status of pipeline:

Clinical Trials Project Target Discovery Preclinical Phase I Ph Ib/IIa Ph II P o C Hep C p7 HIV Vpu Dengue M protein + other targets

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

– The Silent Killer
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

• 170 m people infected worldwide; 4 m patients in US (2.7m chronic infection)

• Majority remain asymptomatic for decades before developing cirrhosis or liver cancer

• US surgeon general considers hepatitis C is one of the most significant public health threats facing US.

• 40 – 50% of liver transplants are due to HCV

• Existing therapies ineffective and toxic

• Documented need for new, safer drugs

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

He C – An Ex andin Market
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

Worldwide market ~US$2.8 billion; predicted to expand to >US$10 billion as new, safer drugs enter the market. O l ll t tl i n y sma percen age curren y rece ve treatment.

USA and Europe represent major markets but other, larger markets are emer g in g .

==> picture [721 x 68] intentionally omitted <==

Smith Nature Reviews Drug Discovery 5, 715–716 (September 2006)

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

C Lead Product – BIT225
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

• BIT225 i s a new i nves ti ga ti ona l ora l sma ll mo ecu e l l d rug i n d eve opmen l t for treating Hep C infection

• Completed two clinical trials:

• –

• Phase Ia 48 patient, single dose safety study in healthy volunteers; Status - com leted p

• -

• Phase Ib 18 patient, 7-day multiple dose study in patients with Hepatitis C Virus infection; Status - completed

• –

• Phase IIa 24 patient, 28-day multiple dose study in patients with Hepatitis C infection (genotype 1)

• Combination with pegylated Interferon and Ribavirin.

• Status trial commenced Sept 2010 and due to complete late 1Q 2011.

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

BIT225 Clinical Information
----- End of picture text -----

 Fi rs - n-c ass rug arge t i l d t ti ng p 7 pro e n o t i f H ep C v rus i

 p7 - Critical role in production of infectious Hep C virus in infected cells  w u tic inter v ention Proposed as ne target for therape

• Phase Ia results

---

• BIT225 was well tolerated at doses up to 600mg with no dose limiting toxicities

• Ph ase I b r esu l ts

• 200 mg BIT225 significantly reduced virus levels compared to placebo (p=0.0002)

• On an individual level, 3 of the 6 subjects receiving 200 mg of BIT225 had significant reductions in viral loads

• Results were first indication that a p7-inhibitor has therapeutic potential

==> picture [721 x 68] intentionally omitted <==

• Focused on saleable to a developing product pharmaceutical partner(s)

• Future Hep C therapies expected to be a cocktail of drugs

• In short term new drugs to be used with current approved drugs interferon (IFN) and ribavirin

• Industry focus on developing new, specific antiviral drugs to use in combination

• P7-inhibitors e.g. BIT225 are potential new additions to this mix

• Biotron is well positioned to partner with either current OR future therapies as synergistic with BOTH

• BIT225 expected to have significantly higher potency in combination w t i h i nter eron an f d r ib av r n on i i b as s o i f prec li n ca i l d ata

• • Phase II trial is a combination study of BIT225 with interferon and ribavirin

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

He C Phase II Combination Trial
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

		Ph II Trial Period	Ph II Trial Period		Trial design
8	pts	0 2 BIT225 (400mg) + IFN/rib Placebo		4	Weeks 44 wks Interferon + Ribavirin
8	pts	BIT225 (200 + IFN/rib	mg)		Interferon + Ribavirin
8	pts	BIT225 (400 + IFN/rib	) mg		I t f Rib i i n er eron + av r n

• Pts randomly assigned to receive either placebo or BIT225 twice daily for 28 days commencement of standard combination therapy for Hep C (IFN/ribavirin)

• Patients continue after 28 days just on IFN/ribavirin as part of their standard treatment (external to Phase II trial)

• 24 patients, genotype 1

• Trial commenced Sept 2010 in Thailand

• Clinical phase expected to be complete Q1 2011

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

Biotron ’
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

• First-in-class new anti-HIV drug targeting HIV-Vpu protein

• N e w m ode o f act i o n – inhi b i ts budd in g o f vir us fr o m inf ected ce ll s

• Targets HIV in viral reservoirs in vivo

• Reservoirs are last of the holy grail in HIV

• No existing drugs target this source of HIV in the body

• Eradication of reservoirs is essential for “cure” of HIV

• Completed Phase I safety trial in healthy volunteers

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

Human Reservoirs cells infected with HIV –
Untreated (A) and Treated with BIT225 (B)
----- End of picture text -----

==> picture [721 x 474] intentionally omitted <==

----- Start of picture text -----

A B
Damaged, non-
Healthy HIV
infectious HIV
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

- -
HIV Phase Ib/IIa Proof of
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

• Phase Ib/IIa trial protocols finalised

• 20 subject trial in HIV+ patients

• Trial designed to demonstrate proof-of-concept

•i.e. can reduce HIV loads in HIV-infected reservoir cells in man

• •Commencement is subject to funding availability

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

• Developing first-in-class antiviral drugs

• Successfully completed two human trials of BIT225

• Good safety and promising efficacy results

• Pivotal Phase IIa Hep C trial results anticipated early 2Q 2011

• P otent a to com i l bi ne BIT22 5 w t i h current or next generat on ep i H C drugs

• Biotron has back up drugs and proprietary assays to facilitate development of 2[nd] generation drugs

• Novel approach to treating HIV reservoirs anticipated to commence Phase Ib/IIa trial subject to funding

• Additional early stage drug discovery projects for Dengue and others

• –

• Strong patent protection 5 patent families filed worldwide

==> picture [721 x 203] intentionally omitted <==

Michelle Miller M anag ng i Di rec or t +61 2 9805 0488 + 61 412 313329 mmiller@biotron.com.au www . biotron . com . au

==> picture [721 x 136] intentionally omitted <==

----- Start of picture text -----

. . .
----- End of picture text -----